Double maintains 2 strategies that include NTLA - Intellia Therapeutics, Inc.
Current Value
$9.951 Year Return
Current Value
$9.951 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| GNOM | 69.77% | $44.38M | 0.5% |
| ARKG | 66.83% | $1.02B | 0.75% |
| XBI | 60.73% | $4.84B | 0.35% |
| IBB | 56.94% | $5.28B | 0.45% |
| IWC | 55.49% | $817.74M | 0.6% |
| PBE | 53.49% | $223.86M | 0.58% |
| IWO | 52.48% | $11.53B | 0.24% |
| IWM | 51.82% | $63.18B | 0.19% |
| VTWO | 51.70% | $12.58B | 0.07% |
| KJUL | 51.32% | $119.28M | 0.79% |
| SCHA | 50.10% | $17.26B | 0.04% |
| BBH | 49.97% | $329.37M | 0.35% |
| KJAN | 49.95% | $287.49M | 0.79% |
| GSSC | 49.75% | $560.96M | 0.2% |
| ARKK | 49.68% | $6.78B | 0.75% |
| PRFZ | 49.25% | $2.36B | 0.34% |
| XRT | 49.19% | $309.43M | 0.35% |
| IWN | 49.05% | $10.93B | 0.24% |
| KOMP | 49.01% | $2.28B | 0.2% |
| ESML | 48.90% | $1.84B | 0.17% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VTEB | -0.01% | $37.62B | 0.03% |
| IBMS | 0.06% | $88.27M | 0.18% |
| FLMI | -0.08% | $723.28M | 0.3% |
| TFI | -0.09% | $3.21B | 0.23% |
| IUSB | -0.11% | $32.92B | 0.06% |
| BLV | -0.12% | $5.66B | 0.03% |
| TAXF | 0.25% | $488.67M | 0.29% |
| PZA | -0.26% | $2.84B | 0.28% |
| NUAG | 0.30% | $58.63M | 0.19% |
| FBND | -0.38% | $19.20B | 0.36% |
| JSI | 0.40% | $865.26M | 0.49% |
| SUSB | 0.47% | $987.13M | 0.12% |
| LTPZ | -0.51% | $669.63M | 0.2% |
| WEAT | -0.54% | $117.67M | 0.28% |
| MTBA | 0.56% | $1.37B | 0.17% |
| AVIG | 0.60% | $1.10B | 0.15% |
| SHYD | -0.63% | $332.28M | 0.35% |
| UNG | 0.64% | $388.31M | 1.06% |
| MMIN | -0.65% | $335.49M | 0.3% |
| GNMA | 0.66% | $367.52M | 0.1% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -41.79% | $295.67M | 1.43% |
| VIXY | -34.88% | $165.58M | 0.85% |
| TAIL | -34.79% | $99.49M | 0.59% |
| SPTS | -17.25% | $5.77B | 0.03% |
| ULST | -16.51% | $658.54M | 0.2% |
| IVOL | -15.40% | $348.25M | 1.02% |
| XONE | -15.19% | $585.85M | 0.03% |
| UTWO | -14.35% | $379.27M | 0.15% |
| IBTI | -13.54% | $1.06B | 0.07% |
| CLIP | -13.34% | $1.51B | 0.07% |
| IBTH | -13.00% | $1.60B | 0.07% |
| SCHO | -12.86% | $11.46B | 0.03% |
| IEI | -12.56% | $15.41B | 0.15% |
| VGSH | -12.45% | $22.77B | 0.03% |
| VGIT | -12.36% | $31.79B | 0.04% |
| SCHR | -12.25% | $11.10B | 0.03% |
| SHYM | -12.22% | $354.58M | 0.35% |
| IBTJ | -12.16% | $684.86M | 0.07% |
| AGZ | -12.09% | $613.46M | 0.2% |
| STPZ | -11.96% | $450.05M | 0.2% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 67.18% | $4.19B | -8.67% | 0.00% |
| BEAM | 65.55% | $1.76B | -22.33% | 0.00% |
| ABCL | 57.91% | $1.04B | +25.99% | 0.00% |
| RXRX | 57.54% | $2.09B | -28.35% | 0.00% |
| DNLI | 53.88% | $2.03B | -35.83% | 0.00% |
| FATE | 53.10% | $130.68M | -64.60% | 0.00% |
| CRBU | 52.83% | $116.26M | -21.88% | 0.00% |
| IDYA | 52.39% | $1.85B | -37.37% | 0.00% |
| ALLO | 52.27% | $258.10M | -45.37% | 0.00% |
| EYPT | 51.61% | $657.15M | +19.23% | 0.00% |
| ARCT | 49.85% | $352.30M | -39.53% | 0.00% |
| ARWR | 49.44% | $2.22B | -36.20% | 0.00% |
| SDGR | 49.42% | $1.51B | +1.38% | 0.00% |
| DNA | 48.63% | $630.84M | -18.04% | 0.00% |
| EDIT | 47.87% | $188.35M | -50.44% | 0.00% |
| RGNX | 47.67% | $414.70M | -23.44% | 0.00% |
| XNCR | 47.40% | $574.35M | -55.81% | 0.00% |
| NVEC | 46.76% | $358.19M | +3.16% | 5.39% |
| MGNX | 46.50% | $79.49M | -69.27% | 0.00% |
| ALEC | 46.34% | $141.99M | -67.28% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CBOE | -19.44% | $24.29B | +35.36% | 1.09% |
| ED | -16.40% | $36.31B | +13.27% | 3.35% |
| CME | -15.15% | $99.25B | +39.75% | 3.87% |
| LITB | -11.84% | $22.07M | -77.41% | 0.00% |
| EXC | -11.74% | $43.82B | +25.72% | 3.63% |
| MOH | -8.33% | $16.60B | +4.89% | 0.00% |
| K | -7.79% | $27.71B | +40.85% | 2.85% |
| T | -7.79% | $207.81B | +53.45% | 3.83% |
| MO | -7.43% | $97.93B | +26.25% | 6.95% |
| AMSF | -7.41% | $832.88M | +5.01% | 3.52% |
| DUK | -7.23% | $92.39B | +19.10% | 3.55% |
| CNC | -7.07% | $28.19B | -14.41% | 0.00% |
| AEP | -7.00% | $55.76B | +19.14% | 3.55% |
| COR | -6.81% | $57.24B | +32.73% | 0.74% |
| VHC | -6.36% | $48.79M | +87.46% | 0.00% |
| MCK | -4.93% | $90.90B | +24.44% | 0.39% |
| TMUS | -4.21% | $274.22B | +34.19% | 1.37% |
| IMNN | -3.98% | $15.87M | -37.00% | 0.00% |
| LRN | -3.96% | $6.16B | +105.86% | 0.00% |
| AWK | -3.83% | $27.80B | +10.98% | 2.21% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| GFI | -0.05% | $21.24B | +58.84% | 2.32% |
| ALHC | -0.18% | $2.81B | +80.33% | 0.00% |
| PPL | -0.23% | $25.13B | +23.96% | 3.15% |
| TEF | -0.29% | $30.02B | +27.27% | 6.13% |
| WEC | -0.29% | $33.43B | +34.23% | 3.33% |
| AEE | 0.35% | $26.67B | +34.81% | 2.88% |
| PPC | -0.36% | $10.79B | +32.45% | 0.00% |
| PHYS.U | 0.43% | - | - | 0.00% |
| CTRE | 0.47% | $5.84B | +20.16% | 4.10% |
| WRB | 0.49% | $27.64B | +40.68% | 0.46% |
| CARV | -0.53% | $8.73M | +25.55% | 0.00% |
| ELV | 0.66% | $89.42B | -26.15% | 1.86% |
| KO | 0.70% | $308.49B | +13.49% | 2.78% |
| MUSA | -0.72% | $8.23B | -9.39% | 0.46% |
| CL | -0.79% | $74.59B | -4.24% | 2.20% |
| IFRX | 0.92% | $53.71M | -53.76% | 0.00% |
| CODI | -1.01% | $480.76M | -70.70% | 15.48% |
| KMB | -1.07% | $43.67B | -4.62% | 3.76% |
| PM | -1.11% | $276.33B | +74.67% | 3.05% |
| LFVN | 1.14% | $168.56M | +113.90% | 1.24% |
Yahoo
Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.
Yahoo
CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.
Yahoo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. It presented encouraging three-year follow-up data from their Phase 1 trial of lonvoguran ziclumeran (lonvo-z) in patients with hereditary angioedema (HAE) at the EAACI Congress 2025. All 10 patients were free of attacks and treatment for a median […]
Yahoo
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Yahoo
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Yahoo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while maintaining a price target of $30.00. This whopping 237% upside from the current price followed the company’s positive three-year data for its hereditary angioedema (HAE) treatment […]
